Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Toceranib Phosphate (SU11654 phosphate) 是有效的、具有口服活性的酪氨酸激酶 (RTK) 受体抑制剂,能抑制PDGFR,VEGFR,Kit,抑制 PDGFRβ 和 Flk-1/KDR 的Ki 分别为 5 nM 和 6 nM。它具有抗肿瘤和抗血管生成作用,可用于研究犬肥大细胞肿瘤。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 255 | 现货 | ||
10 mg | ¥ 417 | 现货 | ||
25 mg | ¥ 652 | 现货 | ||
50 mg | ¥ 840 | 现货 | ||
100 mg | ¥ 1,263 | 现货 |
产品描述 | Toceranib Phosphate (SU11654 phosphate), is a selective inhibitor of the tyrosine kinase activity of several members of the split kinase RTK family, including Flk-1/KDR, PDGFR |
靶点活性 | PDGFRβ:5 nM (Ki), Flk-1:6 nM (Ki) |
体内活性 | Systolic blood pressure was significantly (P = 0.0013) higher in previously normotensive treatment dogs after initiation of treatment with toceranib phosphate (152 mmHg ± 19) compared to baseline (136 mmHg ± 14). 37% of treated dogs developed SBP ≥ 160 mmHg. The prevalence of systemic hypertension (37%) and proteinuria (21%) at baseline in treatment dogs did not differ from that of age-matched healthy controls (15% [P = 0.13] and 0% [P = 0.069], respectively)[1]. |
动物实验 | Dogs scheduled to received toceranib phosphate treatment were divided into 2 groups based on SBP recorded at screening: dogs that were normotensive were assigned to Group 2a and dogs diagnosed with HT were assigned to Group 2b. After baseline evaluation, dogs enrolled in Group 2a received toceranib phosphate at a standard dose as previously published.2 Group 2b dogs received toceranib phosphate as described, but were also treated with standard‐of‐care treatment for HT, including amlodipine besylate (0.2–0.4 mg/kg PO q 24 hours), enalapril maleate (0.5 mg/kg PO q 12 hours), or both, initiated at the discretion of the attending veterinarian. Some dogs were treated with additional medications, including corticosteroids, at the discretion of the oncologist. All dogs were re‐evaluated on Day 14 (±3 days) at which time a UPC and blood pressure measurements were performed[1]. |
别名 | SU11654 phosphate, PHA 291639 phosphate, 托西尼布磷酸盐 |
分子量 | 494.45 |
分子式 | C22H28FN4O6P |
CAS No. | 874819-74-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Slightly soluble
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Toceranib Phosphate 874819-74-6 Angiogenesis Proteases/Proteasome Tyrosine Kinase/Adaptors VEGFR Tyrosinase PDGFR c-Kit SU11654 inhibit SU11654 Phosphate SU11654 phosphate SU-11654 Toceranib SU 11654 Phosphate PHA 291639E Platelet-derived growth factor receptor PHA 291639 Phosphate PHA291639 Phosphate CD117 PHA 291639 phosphate SU-11654 Phosphate Vascular endothelial growth factor receptor 托西尼布磷酸盐 SU 11654 SCFR PHA-291639 Phosphate Inhibitor inhibitor